Opportunity
SBIR / STTR #75N98026R00109
Development of Devices, Diagnostics, and Digital Health Tools for Pediatric and Rare Cancers (HHS, NIH SBIR/STTR)
Buyer
National Institutes of Health
Posted
October 04, 2023
Respond By
September 21, 2026
Identifier
75N98026R00109
NAICS
541715, 541714
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), is seeking proposals from small businesses to develop innovative devices, diagnostic technologies, and digital health tools for pediatric and rare cancers. - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Cancer Institute (NCI) SBIR Development Center - OEMs and Vendors: - No specific OEMs or vendors are mentioned in the solicitation - Products/Services Requested: - Development of devices, diagnostics, and digital health tools for the treatment, detection, and diagnosis of pediatric and rare cancers - Activities may include clinical validation, safety studies for devices, and biomarker optimization for diagnostics - Focus on high-risk, innovative, and disruptive technologies with strong scientific rationale - Entrepreneurship training and commercialization planning support included - Unique or Notable Requirements: - Emphasis on addressing unmet needs in pediatric and rare cancers - Encourages high-risk, out-of-the-box ideas with a sound scientific premise - Applicants must be small businesses - No specific products, part numbers, or purchase quantities are listed
Description
This solicitation seeks applications for the development of innovative devices, diagnostic technologies, or digital health tools aimed at improving treatment, detection, and diagnosis of pediatric and rare cancers. The focus is on high-risk, disruptive technologies that can improve patient survival or address significant unmet medical needs where current standards have limited progress. Projects may include device development with clinical validation and safety studies, or diagnostics development involving biomarker optimization and assay validation. The program also supports entrepreneurship training and commercialization planning to explore the commercial potential of the technology.